id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-336735-pk7sx81r	Veerapandiyan, Aravindhan	Spinal muscular atrophy care in the COVID‐19 pandemic era	2020-05-03		.txt	text/plain	1422	95	48	The coronavirus disease 2019 (COVID‐19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). 9 Currently available US Food and Drug Administration-approved therapies for spinal muscular atrophy (SMA), nusinersen and onasemnogene abeparvovec-xioi, [10] [11] [12] are life altering and are reshaping the natural history of the disease, resulting in improved survival and motor function. 16, [18] [19] [20] We emphasize that treatment decisions should be individualized and made cohesively between the patient, family, and healthcare provider, taking into account any geographicor institution-specific policies and precautions for COVID-19. 9 We continue to recommend urgent evaluation of infants with SMA identified by NBS with rapid initiation of treatment while following the regional and institutional policies pertaining to the public health emergency and maximizing the safety of patients and caregivers. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives Spinal muscular atrophy care in the COVID-19 pandemic era	./cache/cord-336735-pk7sx81r.txt	./txt/cord-336735-pk7sx81r.txt